Last reviewed · How we verify
Pilocarpine Ophthalmic Solution
Pilocarpine is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity in the eye to increase aqueous humor outflow and reduce intraocular pressure.
Pilocarpine is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity in the eye to increase aqueous humor outflow and reduce intraocular pressure. Used for Glaucoma and ocular hypertension, Dry eye syndrome (xerophthalmia).
At a glance
| Generic name | Pilocarpine Ophthalmic Solution |
|---|---|
| Also known as | Glaupin 1%, MicroLine, AGN-190584, VUITY |
| Sponsor | Maastricht University Medical Center |
| Drug class | Muscarinic receptor agonist |
| Target | Muscarinic acetylcholine receptor (M3) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Pilocarpine binds to muscarinic M3 receptors on the ciliary muscle and iris sphincter muscle, causing contraction (miosis and accommodation). This mechanical action opens the trabecular meshwork and Schlemm's canal, facilitating drainage of aqueous humor and lowering intraocular pressure. It is a direct-acting parasympathomimetic agent used topically in ophthalmology.
Approved indications
- Glaucoma and ocular hypertension
- Acute angle-closure glaucoma
Common side effects
- Miosis (pupil constriction)
- Accommodative spasm (blurred vision)
- Ocular irritation and discomfort
- Brow ache
- Conjunctival hyperemia
Key clinical trials
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE3)
- Pilocarpine Use After Kahook Goniotomy (PHASE3)
- Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE2)
- Evaluation of NV701 (Pilocarpine 1.25%) Compared With Vuity (Pilocarpine 1.25%) on Pupil Size in Subjects With Presbyopia (EARLY_PHASE1)
- Quality of Life in Presbyopic Patients Who Are Treated With Qlosi (PHASE4)
- Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in Children (NA)
- Efficacy of Pilocarpine As a Secretagogue Versus Artificial Tears for the Treatment of Dry Eye (NA)
- A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pilocarpine Ophthalmic Solution CI brief — competitive landscape report
- Pilocarpine Ophthalmic Solution updates RSS · CI watch RSS
- Maastricht University Medical Center portfolio CI